SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics presented results showing a refined approach to detect drug-induced testicular toxicity using Singlera’s cell-free DNA methylation ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

A Japanese man, who was detained by Chinese authorities, will likely continue to remain in detention despite the Japanese ...

Emergen Research Logo The increasing prevalence of liver diseases worldwide is a major growth driver in the liver disease therapeutics mark ...

The "Cholera Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been ...

Astellas signed a memorandum of agreement with Yaskawa in May 2024. Credit: yu_photo/Shutterstock. Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...

Astellas Pharma and Yaskawa Electric have signed a definitive agreement to establish a joint venture aimed at advancing cell therapy manufacturing through automation. According to Astellas, the ...

Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.

RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical ...

DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix ...

1 Day ALPMY 0.10% DJIA -1.48% S&P 500 -1.76% Health Care/Life Sciences -0.37% ...